E to Week488 Journal of International Health-related Study 44(3)Figure 2. Patient disposition in a Norwegian trial comparing the efficacy and security of celecoxib 200 and 400 mg once each day (qd) and diclofenac 50 mg 3 times every day (tid) in therapy of ankylosing spondylitis.Walker et al.Figure three. Adjust from baseline in Global Discomfort Intensity at Week 12 in Norwegian sufferers with ankylosing spondylitis treated with celecoxib 200 or 400 mg each day (qd) or diclofenac 50 mg 3 times day-to-day (tid): intention-to-treat population. LS imply, least squares mean.Table 1. Modifications from baseline in secondary efficacy endpoints at Week 12 in Norwegian patients with ankylosing spondylitis stratified according to therapy group (celecoxib 200 or 400 mg everyday [qd] or diclofenac 50 mg three instances day-to-day [tid]): intention-to-treat population. Celecoxib Parameter Nocturnal pain, n Baseline Week 12 LS imply modify from baselinea Distinction in LS mean (95 CI) Celecoxib vs diclofenaca,b,c Celecoxib 200 mg vs celecoxib 400 mga,b,c BASFI, n Baseline Week 12 LS mean adjust from baselinea Difference in LS mean (95 CI) Celecoxib vs diclofenaca,b,c Celecoxib 200 mg vs celecoxib 400 mga,b,c BASDAI, n Baseline Week 12 LS mean change from baselinea 200 mg group 107 61.3 24.two 35.9 26.3 five.9 two.5 2.1 (.3, 9.five) 7.2 (.four, 14.158326-85-3 Order 7) 107 48.1 21.eight 34.0 21.two four.9 1.8 three.two (.1, 8.6) three.3 (.two, eight.7) 107 58.four 20.7 40.Price of 85272-31-7 6 21.0 17.5 1.9 400 mg group 108 57.9 23.three 27.six 23.4 three.1 two.five .1 (2.5, 2.3) 108 45.5 22.1 29.4 22.7 8.two 1.eight .04 (.four, 5.3) 107 52.8 19.3 33. 21.six 0.8 1.9 Diclofenac group 115 62.0 21.7 34.4 25.7 8.0 two.four 113 48.three 20.1 30.8 20.0 8.1 1.7 114 56.2 18.eight 37.five 21.3 9.five 1.(continued)Table 1. Continued.Journal of International Health-related Research 44(3)Celecoxib Parameter Difference in LS mean (95 CI) Celecoxib vs diclofenaca,b,c Celecoxib 200 mg vs celecoxib 400 mga,b,c Physician’s International Assessment of Illness Severity, n Baseline Week 12 LS mean modify from baselinea Distinction in LS imply (95 CI) Celecoxib vs diclofenaca,b,c Celecoxib 200 mg vs celecoxib 400 mga,b,c Patient’s International Assessment of Illness Severity, n Baseline Week 12 LS mean transform from baselinea Distinction in LS imply (95 CI) Celecoxib vs diclofenaca,b,c Celecoxib 200 mg vs celecoxib 400 mga,b,c ASAS 20 responders, n ( )d Responders at Week 12 200 mg group two.PMID:35991869 0 (.7, 7.six) three.3 (.5, 9.1) 107 58.3 16.6 36.six 18.7 1.1 two.0 1.8 (.0, 7.five) two.5 (.4, 8.3) 105 65.9 19.6 43.four 24.7 three.0 two.7 three.5 (.4, 11.four) 5.0 (.0, 13.0) 107 55 (51.four) 400 mg group .three (.0, 4.three) 108 55.2 17.0 33.1 20.0 3.5 1.9 .7 (.5, five.1) 107 62.6 21.3 37.2 25.four 8.1 2.7 .5 (.4, six.4) 108 65 (60.2) Diclofenac group 114 59.0 16.three 35.6 20.7 2.9 1.9 112 67.five 18.0 40.7 26.7 6.5 two.6 115 66 (57.four)Data presented as: n or n ( ) patients; 95 CI; imply SD (baseline and Week 12 data); imply SEM (LS mean change from baseline). a Derived from analysis of covariance with baseline as a covariate, and remedy and centre as aspects. b Calculated as difference amongst treatment groups in adjust from baseline. A negative distinction indicates a numerical superiority of celecoxib over diclofenac. c Tukey ramer numerous comparison procedure utilised to create self-confidence interval and P-value. d Pairwise comparisons amongst treatment groups at Week 12 were produced employing Fisher’s precise test. No considerable between-group differences (200 mg qd celecoxib vs diclofenac, 400 mg celecoxib vs diclofenac, or 200 mg celecoxib vs 400 mg celecoxib; P ! 0.05). BASFI, Bath Ankylosing Spondylitis Functional Index; BAS.